Please login to the form below

Not currently logged in
Email:
Password:

Sprout Pharmaceuticals

This page shows the latest Sprout Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Rare disease therapies head the ‘class of 2015’

Rare disease therapies head the ‘class of 2015’

Kythera Biopharma created a new therapeutic category in the pharma/cosmetic area with Kybella (deoxycholic acid), the first drug for reducing double chin, while Sprout Pharma chalked up the first approval ... hypoactive sexual desire disorder. serotonin 5

Latest news

  • Valeant swoops on Sprout to claim female sexual disorder drug Valeant swoops on Sprout to claim female sexual disorder drug

    female sexual disorder, with Sprout shareholders in line for a share of future profits from the new drug. ... Sprout will become an operating division of the Canadian firm run by current chief executive Cindy Whitehead.

  • FDA approves first female sexual disorder drug FDA approves first female sexual disorder drug

    Sprout Pharmaceuticals' Addyi has become the first drug to be approved in the US for reduced sexual desire in women. ... This profile means that Sprout has had to develop a Risk Evaluation and Mitigation Strategy (REMS) to make sure the new drug is used

  • FDA panel backs Sprout Pharma's 'female Viagra' FDA panel backs Sprout Pharma's 'female Viagra'

    Could be approved for HSDD in pre-menopausal women. Sprout Pharmaceuticals has moved a step closer to securing approval for a drug to treat reduced libido in women after getting a ... drug. Sprout acquired rights to the programme in 2011 and says it

More from news
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    Immuno-oncology combinations in lung cancer. Not disclosed. Peregrine Pharmaceuticals. Combination clinical trials. ... This month the deal was the purchase of Sprout Pharmaceuticals for $1bn cash in two instalments of $500m bringing the recently

  • Pharma deals during October 2013 Pharma deals during October 2013

    Auven's portfolio of companies includes Resolvyx, Kiacta, Kolitan and Sprout Pharmaceuticals, as well as Spirogen and ADC Therapeutics. . ... Options to acquire. In a double announcement Sideris Pharmaceuticals reported the successful completion of its

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics